

Haematologica
HAEMATOL/2018/196014
Version 1

Still a Role for 2nd Line Chemoimmunotherapy in Chronic Lymphocytic
Leukemia?

Jennifer R Brown

Disclosures: No support received for this work. JRB has served as a consultant for Janssen, Pharmacyclics, Astra-Zeneca, Sun, Beigene, Sunesis, Loxo, Gilead, TG Therapeutics, Verastem, Abbvie, Pfizer, Celgene, Novartis and Genentech, and receives research funding from Sun, Verastem, Loxo and Gilead.